Recently, Immunotherapies of advanced NSCLC with antibodies against PD-1 or PD-L1 has shown significant clinical efficacy 39, but there are few predictive biomarkers to identify patients who can benefit from immune checkpoint inhibitors (ICIs) treatment. This evidence concerns the gene CD274 and non-small cell lung carcinoma.